Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

ImClone’s Late-stage Pipeline Includes A Potential Erbitux Competitor

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.

You may also be interested in...



ImClone Narrows Focus To VEGFR2 In Breast Cancer Phase III Trial

Pivotal study is expected this year with the compound in gastric tumors as well.

ImClone Narrows Focus To VEGFR2 In Breast Cancer Phase III Trial

Pivotal study is expected this year with the compound in gastric tumors as well.

Is Bristol-Myers Squibb’s ImClone Takeover Bid A Preemptive Grab?

BMS takeover bid may be aimed at thwarting a spin-off, controlling potential Erbitux competition.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS068298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By